若生智能
Drug Database
NI

nitroglycerin (Millisrol Tape)

✓ Approved

Nippon Kayaku Co.,Ltd. · 小分子 · 小分子

什么是 nitroglycerin？

nitroglycerin 是一种小分子，由Nippon Kayaku Co.,Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Transdermal。

药物档案

商品名Millisrol Tape
公司Nippon Kayaku Co.,Ltd.
药物类别小分子
给药途径Transdermal
状态Approved
来源： ClinicalTrials.gov, Nippon Kayaku Co.,Ltd.

治疗适应症

nitroglycerin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved

相关研究文献

PubMedAdvances in therapy2026-08-04

Pharmacokinetics at Different Application Sites and Dermal Safety Analysis of Dextroamphetamine Transdermal System (d-ATS) in Healthy Adults and Patients with ADHD.

Mattingly Gregory W GW, Haj-Ibrahim Houda H, Komaroff Marina M, Meeves Suzanne S et al.

Dextroamphetamine transdermal system (d-ATS) is the first and only amphetamine-based transdermal system FDA-approved for attention-deficit/hyperactivity disorder (ADHD) in adults and children aged ≥ 6 years, providing an alternative to oral stimulants. Although transdermal systems can cause local skin reactions, in the d-ATS pivotal study, no discontinuations due to patch application site reactions occurred, and discomfort/pain typically resolved within 2-4 h post-application. d-ATS is approved for five bilateral application sites (10 unique locations). This paper evaluates the pharmacokinetic (PK) bioequivalence between different application sites and summarizes dermal safety and irritation findings from four d-ATS clinical studies (studies 1-4). The application site PK bioequivalence study was a single-dose, open-label, 5-way crossover study assessing amphetamine bioavailability, discomfort, and irritation in healthy adults after a 9 h application of 20 mg/19.05 cm2 d-ATS to five distinct sites. Other studies, studies 1-4, conducted in healthy adults or patients with ADHD, evaluated dermal irritation from d-ATS alone or vs placebo under intended-use or exaggerated-use conditions. The application site PK study population included 50 patients. All 90% CIs for key exposure parameters fell within the FDA-specified bioequivalence limit of 80-125%, demonstrating bioequivalence across five application sites, with no discontinuations related to irritation or discomfort. Under intended-use conditions (site rotation consistent with approved d-ATS use; studies 1 and 2), instances of skin irritation were not clinically meaningful (≥ 3 point Bowman and Berger scale combination score). Under exaggerated-use conditions consistent with FDA guidance (studies 3 and 4), clinically meaningful irritation occurred in 55-61% of patients; 3/249 discontinued because of d-ATS-associated skin irritation, which generally resolved within 15-27 h after patch removal. d-ATS's benefits as an additional treatment option for ADHD in children, adolescents, and adults likely outweigh any minor irritation concerns. Transdermal delivery confers practical advantages, and the range of bioequivalent application sites can help minimize dermal irritation. d-ATS's efficacy has been established in prior clinical studies and published elsewhere. Overall, d-ATS represents a valuable, flexible treatment option for children and adolescents with ADHD.

PMID 42547686
阅读全文 →
PubMedJournal of materials chemistry. B2026-08-04

Development of multifunctional nanomaterials for advanced theranostic applications in skin cancer.

Hsieh Yu-Lung YL, Xie Jun J, Jiang Shaohua S, Chen Junwei J et al.

Skin cancer is a highly heterogeneous malignancy with increasing incidence and limited therapeutic efficacy from conventional treatments due to poor specificity, inadequate drug penetration, and resistance. Nanomaterial-based platforms have emerged as promising strategies to address these challenges by enabling precise diagnosis and targeted therapy. This review summarizes recent advances in nanomaterial-mediated theranostics for skin cancer, including organic, inorganic, and biomimetic or hybrid nanosystems. Their roles in enhancing drug delivery through passive and active targeting, improving transdermal penetration, and enabling controlled release are highlighted. Emerging diagnostic approaches based on nanotechnology, such as imaging and biosensing, are also discussed for sensitive and noninvasive detection. In addition, nanoplatform-enabled multimodal therapies that integrate chemotherapy, phototherapy, gene therapy, and immunotherapy are presented, with particular emphasis on microneedle-assisted transdermal systems. Despite the remaining challenges in terms of biosafety, scalability, and clinical translation, nanomaterials offer significant potential for advancing precise and personalized skin cancer management.

PMID 42549516
阅读全文 →
PubMedJournal of computer-aided molecular design2026-08-04

Comparative analysis of supervised machine learning algorithms for transdermal drug delivery in brain disorders.

Dave Hetalbahen Kiritkumar HK, Thakkar Tejas Harshadbhai TH, Thakkar Vaishali Tejas VT, Dalwadi Saloni Bharatbhai SB

To improve patient compliance and provide stable and prolonged delivery of drugs to the brain, transdermal drug delivery systems (TDDS) are being explored as a viable method of treatment of various brain diseases without the invasion of any organs. Optimization of TDDS remains problematic owing to the complex nonlinear interplay between formulation elements and process factors that affect drug entrapment efficiency, stability, and drug-release properties. Therefore, this study aims to develop a supervised Machine Learning (ML) framework to simultaneously predict multiple critical formulation attributes in brain-targeted TDDS. A dataset comprising 542 formulation records collected from 48 peer-reviewed studies and 6 validated laboratory sources was utilized. Physiochemically informed preprocessing, feature engineering, and Cuckoo Catfish Optimizer (CCO)-based hyperparameter tuning were integrated with multiple supervised learning models, including Linear Regression, Decision Tree, Random Forest, Support Vector Regressor, Gradient Boosting, and Artificial Neural Networks. Seven key formulation outputs, namely entrapment efficiency, drug loading, particle size, PolyDispersity Index (PDI), zeta potential, release time, and drug release, were simultaneously predicted and interpreted using SHapley Additive exPlanations (SHAP). Ensemble models significantly outperform all linear models and the conventional standalone approaches by demonstrating an average R increase of 24.63% compared to the standard models while achieving comparable stability and performance for most of the formulation properties. In addition, SHAP revealed that lipid composition, the type of surfactant, formulation pH, and the temperature used for formulation preparation were the key determinants in formulating successful TDDS, which can ultimately lead to an accurate, interpretable, and scalable decision-support platform that significantly accelerates TDDS development by decreasing the overall experimental workload and allowing data-driven design.

PMID 42550291
阅读全文 →
PubMedPharmaceutical development and technology2026-08-04

Self-Assembled Ufasomes of Unsaturated Fatty Acids: Mechanisms, Characterization, and Drug Delivery Potential.

Bansal Raghavi R, Baloni Deepanshi D, Mishra Manoj Kumar MK

Ufasomes-vesicular systems formed from long-chain unsaturated fatty acids such as oleic acid-have re-emerged as cost-effective, biocompatible alternatives to phospholipid liposomes. These bilayered assemblies self-organize at specific pH conditions and efficiently encapsulate both hydrophilic and lipophilic drugs. Their highly fluid membranes, attributed to cis-double-bond-induced structural disorder, enhance interaction with biological barriers, particularly the stratum corneum, making them valuable for topical and transdermal delivery.This review outlines the chemistry and self-assembly of ufasomes, followed by a critical appraisal of preparation techniques-including thin-film hydration and reverse-phase evaporation-and their influence on vesicle size, stability, and encapsulation efficiency. Advantages such as biocompatibility, biodegradability, and pH-responsive release are highlighted alongside limitations including pH-dependent instability and oxidative susceptibility. Key characterization approaches are summarized, and the therapeutic scope of ufasomes is examined, encompassing enhanced dermal delivery of antifungals and antidepressants, targeted cancer therapy, and improved oral bioavailability of nutraceuticals like oleuropein. The review concludes with emerging strategies to overcome current constraints and perspectives on advancing ufasomes toward clinical translation as versatile drug-delivery systems.

PMID 42550566
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-08-04

Bioelectronic Considerations in Biomedical Microneedles.

Luo Le L, Wu Xiaoting X, Wang Lei L, Chen Xiaoqiang X et al.

Microneedles (MNs), fabricated from diverse materials and assembled into arrays, have emerged as promising platforms for transdermal drug delivery and health monitoring. However, conventional MN-based theranostic systems mainly rely on passive diffusion and often involve complicated operational procedures, limiting delivery efficiency and real-time responsiveness. To overcome these limitations, MNs have been integrated with enhancement strategies such as magnetic fields, acoustics, and electronics to achieve active and programmable biomedical functions. Among these approaches, bioelectronics offer unique advantages in flexibility, conductivity, signal processing, and closed-loop control, thereby expanding the capabilities of MN systems in drug delivery and biosensing. Despite rapid progress, current studies mainly focus on material development and device fabrication, while the underlying design logic of bioelectronic MN systems remains insufficiently discussed. Herein, this review summarizes the recent advances in MN-assisted bioelectronic systems and proposes a bioelectronic design framework based on "front-end," "mid-end," and "back-end" functionalities. This framework provides a systematic understanding of how biointerfaces, signal transduction, and electronic modules cooperatively govern system performance. By highlighting the integration mechanisms and architectural strategies of bioelectronic MNs, this review offers insights into the rational design of next-generation wearable and closed-loop biomedical platforms.

PMID 42549657
阅读全文 →
PubMedBiomaterials2026-08-04

Inflammation-triggered nanodrug delivery microneedles targeting pathogenic COX2+ endothelial cell-mediated glycocalyx degradation to ameliorate psoriasis.

Ou Zelin Z, Zou Keyi K, Zeng Linxi L, Wang Jingyi J et al.

Psoriasis is a chronic, immune-mediated inflammatory skin disorder. The vascular endothelium serves as the final barrier preventing circulating immune cells from entering inflamed skin, yet its role in psoriasis pathogenesis and therapeutic potential has long been overlooked. Here, we identify a pathogenic subpopulation of cyclooxygenase-2 (COX2, encoded by PTGS2) high endothelial cells (COX2+ ECs), characterized by elevated P-selectin expression, excessive oxidative stress, and MMP9-mediated glycocalyx degradation. The ROS-COX2-MMP9 axis can be effectively suppressed by mebendazole, an FDA-approved anthelmintic drug. Guided by this insight, we develop a bioinspired platform (P@Meb-MNs). Mebendazole and a P-selectin-targeting ligand (PSGL-1) spontaneously self-assemble into carrier-free nanoparticles, which are then encapsulated within an MMP9-responsive microneedle matrix. Upon transdermal administration, the microneedles penetrate the hyperkeratotic epidermis and degrade in response to elevated MMP9 levels, releasing P@Meb-NPs. Directed by PSGL-1, these nanoparticles selectively recognize and accumulate in COX2+ ECs, where mebendazole disrupts the ROS-COX2-MMP9 feedback loop, preserves glycocalyx integrity, and suppresses immune cell extravasation. This approach markedly enhances glycocalyx coverage from 11.91 ± 4.09% to 87.5 ± 8.7% and significantly reduces immune cell infiltration. Collectively, this work establishes a vascular-targeted therapeutic paradigm centered on endothelial glycocalyx repair and achieves precise and effective intervention in inflammatory diseases.

PMID 42546583
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nitroglycerin